Polyphyllin VII attenuated RANKL-induced osteoclast differentiation via inhibiting of TRAF6/c-Src/PI3K pathway and ROS production
Open Access
- 19 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Musculoskeletal Disorders
- Vol. 21 (1), 1-10
- https://doi.org/10.1186/s12891-020-3077-z
Abstract
Osteoporosis is a worldwide severe bone disease. This study aimed to evaluate the effect of polyphyllin VII on the genesis of osteoclasts from bone marrow macrophages (BMMs) and its potentiality as a therapeutic drug for osteoporosis. BMMs were induced to differentiate into osteoclasts by RANKL and M-CSF. The cells were then treated with various concentrations of polyphyllin VII. Intracellular reactive oxygen species (ROS) measurement assay, resorption pit formation assay, tartrate-resistant acid phosphatase (TRAP) staining and TRAP activity assessment, cell viability assay, active GTPase pull-down assay, immunofluorescent staining, immunoblotting, and RT-PCR were performed. RANKL + M-CSF significantly increased TRAP activity, number of osteoclasts, number and area of lacunae, intracellular content of ROS, protein levels of Nox1, TRAF6, c-Src and p-PI3K, as well as the content of activated GTP-Rac1, which were significantly blocked by polyphyllin VII in a concentration-dependent manner. These findings suggested that polyphyllin VII inhibited differentiation of BMMs into osteoclasts through suppressing ROS synthesis, which was modulated by TRAF6–cSrc–PI3k signal transduction pathway including GTP-Rac1 and Nox1. Polyphyllin VII could be a therapeutic drug for osteoporosis.Keywords
This publication has 29 references indexed in Scilit:
- Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseasesJournal of Bone and Mineral Metabolism, 2015
- Osteoporosis in the European Union: medical management, epidemiology and economic burdenArchives of Osteoporosis, 2013
- Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumabTherapeutics and Clinical Risk Management, 2012
- The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008Osteoporosis International, 2011
- From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of OsteoporosisEndocrine Reviews, 2010
- Pulmonary Toxicity and Metabolic Activation of Dauricine in CD-1 MiceThe Journal of pharmacology and experimental therapeutics, 2009
- Oxidative stress in bone remodelling and diseaseTrends in Molecular Medicine, 2009
- Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025Journal of Bone and Mineral Research, 2007
- Oxidative StressSports Medicine, 2006
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002